Sanara MedTech (SMTI) AI Stock Analysis

• Market Cap: $301.12M
• Dividend Yield: N/A
• Average Volume (3M): 32.89K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.05
• Revenue Growth: 34.29%
• EPS Growth: -49.21%
• Country: US
• Employees: 141
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.23
• Shares Outstanding: 8,902,351
• 10 Day Avg. Volume: 20,803
• 30 Day Avg. Volume: 32,893
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 2.81
• Enterprise Value/Gross Profit: 3.10
• Enterprise Value/Ebitda: 194.79
• 1Y Price Target: $50.00
• Price Target Upside: 51.06% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 61 Neutral
• Price Target: $36.00 ▲(8.76% Upside)

Sanara MedTech's overall stock score is driven by strong technical indicators and positive earnings call insights, but is tempered by financial challenges and valuation concerns. The company's strategic leadership changes are a positive step towards addressing these issues.

Positive Factors

Revenue Growth

Strong revenue growth in the Surgical segment indicates successful product adoption and market expansion, enhancing long-term business prospects.

Profitability Improvements

Improved profitability in the Surgical segment suggests effective cost management and operational efficiency, supporting sustainable financial health.

Market Expansion

Expanding market reach through a larger customer base and distributor network enhances Sanara's competitive position and revenue potential.

Negative Factors

THP Segment Losses

Ongoing losses in the THP segment indicate challenges in achieving profitability, potentially diverting resources from more successful areas.

Increased Operating Expenses

Rising operating expenses could pressure margins and reduce profitability, challenging the company's ability to sustain financial improvements.

Reliance on Debt Financing

Increased reliance on debt can strain financial flexibility and elevate risk, potentially impacting long-term stability and growth initiatives.

Sanara MedTech Business Overview & Revenue Model

Company Description

Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako's Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako's Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako's Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

How the Company Makes Money

Sanara MedTech generates revenue through the sale of its proprietary wound care and regenerative medicine products, which are marketed to hospitals, clinics, and healthcare providers. The company utilizes a direct sales force and distribution partnerships to reach its target markets effectively. Key revenue streams include product sales, licensing agreements, and potentially reimbursement from insurance providers for its medical solutions. Strategic partnerships with healthcare institutions and organizations also enhance its market presence and contribute to its earnings, as they may involve collaborative research, co-marketing arrangements, or joint ventures that expand the company's product offerings and market access.

Sanara MedTech Financial Statement Overview

Summary

Sanara MedTech shows strong revenue growth and a high gross profit margin, but faces challenges with profitability, cash flow, and increased debt reliance. These financial risks need addressing for long-term stability.

Income Statement

Sanara MedTech has shown a positive revenue growth rate of 6.19% in the TTM, indicating a healthy expansion in sales. The gross profit margin is strong at 91.76%, reflecting efficient cost management. However, the company is facing profitability challenges with a negative net profit margin of -10.22% and negative EBIT margin, indicating operational inefficiencies.

Balance Sheet

The company's debt-to-equity ratio has increased to 1.28 in the TTM, suggesting a higher reliance on debt financing, which could pose a risk if not managed carefully. The return on equity is negative, indicating that the company is not generating profits from shareholders' equity. The equity ratio is moderate, showing a balanced asset financing structure.

Cash Flow

The free cash flow growth rate is significantly negative at -102.55%, indicating cash flow challenges. The operating cash flow to net income ratio is low at 0.25, suggesting limited cash generation from operations relative to net income. The free cash flow to net income ratio is also low, pointing to potential liquidity issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	97.24M	86.67M	64.99M	45.84M	24.14M	15.59M
Gross Profit	88.11M	78.53M	57.14M	39.48M	21.83M	13.97M
EBITDA	1.40M	-1.86M	-289.10K	-9.67M	-7.22M	-4.02M
Net Income	-9.94M	-9.66M	-4.30M	-7.94M	-7.92M	-4.36M
Balance Sheet
Total Assets	98.77M	88.09M	73.87M	61.04M	36.40M	9.83M
Cash, Cash Equivalents and Short-Term Investments	16.96M	15.88M	5.15M	8.96M	18.65M	455.37K
Total Debt	45.45M	32.29M	11.79M	819.22K	425.44K	481.38K
Total Liabilities	63.38M	49.18M	29.28M	19.32M	6.24M	3.99M
Stockholders Equity	35.40M	39.40M	44.83M	41.83M	30.64M	6.15M
Cash Flow
Free Cash Flow	58.91K	-229.63K	-3.51M	-6.30M	-5.56M	-5.68M
Operating Cash Flow	3.65M	-23.78K	-3.25M	-5.55M	-4.81M	-4.03M
Investing Cash Flow	-15.59M	-6.61M	-10.21M	-3.51M	-5.28M	-2.74M
Financing Cash Flow	22.76M	17.37M	9.64M	-627.35K	28.30M	622.33K

Sanara MedTech Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 33.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SMTI, the sentiment is Neutral. The current price of 33.1 is below the 20-day moving average (MA) of 34.13, above the 50-day MA of 30.12, and above the 200-day MA of 31.62, indicating a neutral trend. The MACD of 0.88 indicates Positive momentum. The RSI at 50.75 is Neutral, neither overbought nor oversold. The STOCH value of 15.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SMTI.

Sanara MedTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTMD	77 Outperform	202.83M	16.92	11.81%	1.94%	-16.64%	-13.64%
STXS	66 Neutral	262.29M	-10.34	-210.33%	―	33.94%	-6.91%
SMTI	61 Neutral	$301.12M	―	-25.78%	―	34.29%	-49.21%
PDEX	60 Neutral	112.02M	12.56	24.51%	―	23.68%	341.25%
ANGO	55 Neutral	436.00M	-12.96	0.00%	―	-3.76%	81.78%
OSUR	50 Neutral	242.81M	-4.80	-13.40%	―	-49.35%	-285.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Sanara MedTech Corporate Events

Sanara MedTech Appoints New CEO Ahead of Growth

On August 29, 2025, Sanara MedTech‘s Board of Directors appointed Seth D. Yon as the new President and Chief Executive Officer, effective September 15, 2025, succeeding Ronald T. Nixon, who will continue as Executive Chairman. This leadership transition is part of a strategic initiative to position Sanara for future growth, with Mr. Yon bringing extensive experience from his previous roles within the company, contributing to its significant revenue growth. Additionally, Ashley Mackey was designated as the principal accounting officer, succeeding Elizabeth B. Taylor, who remains the Chief Financial Officer.